CDCN's role in the collaboration includes, through its network of physician scientists, partnering with seven academic institutes from around the globe to contribute iMCD, related disease and 'normal' serum samples and analysing the results of the proteomic screen.
The CDCN's innovative approach first involved building a global community of over 400 physicians and researchers, assembling a scientific advisory board of 28 experts from eight countries, and supporting and engaging patients in research prioritization.
Then, the CDCN crowdsourced among the global community to identify gaps in medical knowledge and determine high priority research projects.